$19.07
1.75% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Innoviva Stock price

$19.07
+0.70 3.81% 1M
+3.89 25.63% 6M
+3.03 18.89% YTD
+6.50 51.71% 1Y
+3.71 24.15% 3Y
+7.81 69.36% 5Y
-2.05 9.71% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.34 1.75%
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Key metrics

Market capitalization $1.19b
Enterprise Value $1.43b
P/E (TTM) P/E ratio 11.54
EV/FCF (TTM) EV/FCF 9.05
EV/Sales (TTM) EV/Sales 4.14
P/S ratio (TTM) P/S ratio 3.47
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth 13.16%
Revenue (TTM) Revenue $344.30m
EBIT (operating result TTM) EBIT $135.96m
Free Cash Flow (TTM) Free Cash Flow $157.59m
Cash position $217.00m
EPS (TTM) EPS $1.65
P/E forward 35.98
P/S forward 3.52
EV/Sales forward 4.21
Short interest 35.95%
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

Buy
50%
Hold
50%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
344 344
13% 13%
100%
- Direct Costs 83 83
35% 35%
24%
262 262
8% 8%
76%
- Selling and Administrative Expenses 73 73
22% 22%
21%
- Research and Development Expense 13 13
74% 74%
4%
176 176
31% 31%
51%
- Depreciation and Amortization 40 40
42% 42%
12%
EBIT (Operating Income) EBIT 136 136
29% 29%
39%
Net Profit 145 145
38% 38%
42%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
4 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following u...
Positive
InvestorPlace
2 months ago
Everything is expensive these days including stocks. Amid a raging bull market, it is tough to find affordable stocks to buy.
Positive
InvestorPlace
2 months ago
Finding high-growth stock opportunities is crucial to constructing a stable and prosperous portfolio. Three outstanding businesses set up for remarkable development in 2024 are highlighted here.
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Pavel Raifeld
Employees 112
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today